Erectile Dysfunction Market Size, Share, Growth Analysis, By Product(Viagra, Cialis, Zydena, Levitra), By Region - Industry Forecast 2024-2031

Key market participants in the erectile dysfunction (ED) drugs market are strengthening their market positions by implementing a variety of strategies, including mergers and acquisitions and research partnerships with other businesses, to introduce novel products and solidify their market positions globally. For instance, due to a production error, Sun Pharmaceutical Industries Ltd. announced the recall of their generic medicine Tadalafil in November 2021. A small gap in the availability of generic ED medications used to treat erectile dysfunction patients may result from this recall.

Erectile Dysfunction Market Top Players Company Profiles

• Pfizer Inc.
• Eli Lilly and Company
• Bayer AG
• VIVUS, Inc.
• Dong-A ST Co. Ltd.
• Meda Pharmaceuticals Inc.
• S.K. Chemicals Co. Ltd.
• Teva Pharmaceutical Industries Ltd.
• Endo International plc
• Futura Medical plc
• Apricus Biosciences, Inc.
• Medtronic plc
• Coloplast Corp.
• Boston Scientific Corporation
• Zephyr Surgical Implants
• Urologix, LLC
• American Medical Systems, Inc.
• Augusta Medical Systems, LLC
• Pos-T-Vac Medical

Erectile Dysfunction Market Recent Development

• In August 2022,Lupin launched an oral drug named sildenafil for erectile dysfunction in the United States.
• In May 2022, Aspargo Laboratories, Inc. purchased the prescription brand Bandol from the Spanish specialty pharmaceutical company Laboratorios Rubio S.A. Bandol is used to treat patients with ED problems.
• In March 2022, the US FDA permitted Lupin to commercialize a generic version of Revatio from Viatris Specialty LLC. Lupin's ANDA for sildenafil (10 mg/mL oral suspension) gained this approval.
• In February 2022, Tadalafil MAXON was first approved for marketing authorization by a Polish business, Adamed, under the OTC (over-the-counter) category.
• In January 2022, for its STENDRA erectile dysfunction (ED) medication, Petros Pharmaceuticals Inc., a provider of pharmaceuticals for men's health, started two self-selection trials (avanafil).